

Please try another search
Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis, today...
Investing.com - Lyra (NASDAQ: LYRA) reported first quarter EPS of $-0.440, worse than the analyst estimate of $-0.430. Revenue for the quarter came in at $410K versus the consensus estimate of...
Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced that it has resumed screening and enrollment in ENLIGHTEN II, its second pivotal Phase 3 clinical trial of LYR-210 in patients with CRS. LYR-210...
Investing.com - Lyra (NASDAQ: LYRA) reported first quarter EPS of $-0.460, $0.05 worse than the analyst estimate of $-0.414. Revenue for the quarter came in at $0.00 versus the consensus estimate of...
Investing.com - Lyra reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Lyra announced earnings per share of $-0.400 on revenue of...
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Consumer Services, Consumer Goods and Technology sectors led shares higher. At the close in NYSE, the Dow Jones...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review